Head-To-Head Contrast: Vaxart (NASDAQ:VXRT) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Vaxart (NASDAQ:VXRT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Vaxart and Brainstorm Cell Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$47.40 million	2.22	-$82.46 million	($0.27)	-1.71
Brainstorm Cell Therapeutics	N/A	N/A	-$17.19 million	($3.36)	-0.32

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vaxart and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxart	-431.61%	-110.46%	-62.78%
Brainstorm Cell Therapeutics	N/A	N/A	-528.56%

Analyst Ratings

This is a breakdown of current ratings and target prices for Vaxart and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0	0	2	0	3.00
Brainstorm Cell Therapeutics	0	0	1	0	3.00

Vaxart currently has a consensus price target of $3.00, suggesting a potential upside of 550.90%. Brainstorm Cell Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 2,677.78%. Given Brainstorm Cell Therapeutics’ higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Vaxart.

Risk and Volatility

Vaxart has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Insider and Institutional Ownership

18.0% of Vaxart shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 2.9% of Vaxart shares are held by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.